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Vascular Scaffolds Use for the Treatment of
In-Stent Restenosis and a Bifurcation Lesion
in a Heavily Calciﬁed Diffusely Diseased VesselToru Naganuma, MD,*y Charis Costopoulos, MD,*y Azeem Latib, MD,*y Katsumasa Sato, MD,*y
Tadashi Miyazaki, MD,*y Antonio Colombo, MD*y
Milan, ItalyA 70-year-old man underwent coronary angio-
graphy that demonstrated in-stent restenosis (ISR)
and long calciﬁed disease extending from the leftFigure 1. Coronary Angiogram and Intravascular Ultrasound Images o
(A) Pre-procedural angiogram demonstrating a restenosed 3.5  15-mm
New Jersey) (dotted line) implanted 20 years ago on the proximal LAD an
distal LAD, with involvement of the LAD/diagonal bifurcation (arrows).
aggressive pre-dilation with 3.0- to 3.5-mm noncompliant balloons on L
protruding EES struts (dotted line). (C) Intravascular ultrasound showing
LMS. (D) Palmaz-Schatz stent struts (arrowheads) with evident dissectio
calciﬁcation after rotational atherectomy and pre-dilation (arrows). (F) C
LAD and diagonal-branch (arrows). (G) Dissection in the middle LAD (arro
left anterior descending coronary artery; LMS ¼ left main stem; P-S sten
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coronary artery (LAD), with involvement of the
LAD/diagonal bifurcation (Fig. 1A). After rota-f the Left Coronary System
Palmaz-Schatz stent (Cordis, Johnson & Johnson Company, Warren,
d a long segment of calciﬁed disease extending from the LMS to the
(B) Angiogram after rotational atherectomy with 1.5-mm burr and
AD. A 2.25  12-mm EES in the diagonal ostium with crushed
lumen area of 3.2 mm2 with a vessel diameter of 4.8 mm at the distal
n in the restenosed segment (arrows). (E) Cracked napkin-ring
rushed EES struts on to the LAD vessel wall at the bifurcation of the
ws). EES ¼ everolimus-eluting stent; ISR ¼ in-stent restenosis; LAD¼
t ¼ Palmaz-Schatz stent.tional atherectomy (1.5-mm burr) and aggressive
pre-dilation, a mini-crush technique was utilized
with a 2.25  12-mm everolimus-eluting stent
(EES) implanted in the diagonal ostium. The
protruding EES was crushed with a balloon
(Figs. 1B to 1G), followed by the implantation of a
Figure 2. Optical Coherence Tomography Images Following the Implantation of 3 BVS on the LAD With 3-Month Angiographic Results
(A) Final angiography showing no evidence of residual stenosis on the LAD. (B) Good expansion of the 3.5  28-mm BVS (scaffold area: 10.7 mm2) after post-dilation
with a 4.0-mm noncompliant balloon within the P-S stent of the proximal LAD. (B0) BVS strut on the luminal surface overlying P-S strut in the treated restenosed
segment. (C) Successful mini-crush stenting with a BVS on the LAD and an EES on the diagonal branch. Fully expanded BVS with complete compression of protruded
EES struts (arrows). (D) BVS overlying a well-prepared, cracked calciﬁed lesion (arrows). (E) Adequate expansion of BVS (3.0  28 mm) on a calciﬁed plaque (arrows) in
mid-distal LAD with a scaffold area of 8.9 mm2. (F) Angiographic image at 3 months with no evidence of scaffold recoil and restenosis. BVS ¼ bioresorbable vascular
scaffold; other abbreviations as in Figure 1.
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e463.5  28-mm ABSORB bioresorbable vascular scaffold
(BVS) (Abbott Vascular, Santa Clara, California) that also
covered the restenotic segment. After kissing balloon inﬂa-
tion, 2 further BVS were implanted distally with minimal
overlap. The procedure was completed with the implantation
of a 4.0  12-mm EES in the LMS followed by a 4.5-mm
balloon dilation. Optical coherence tomography demon-
strated a crushed diagonal EES and an adequately
expanded, well-apposed BVS without any evidence of
scaffold disruption (Figs. 2A–2E). Three-month follow-up
angiography showed no evidence of scaffold recoil and
restenosis (Fig. 2F).
Although BVS has been used for complex lesions (1,2),
its use for the treatment of ISR has yet to be reported.
BVS use in this context is particularly attractive because
it avoids the addition of further metal layers, and this, in
conjunction with its greater biocompatibility as compared
with conventional stents, can potentially reduce the risk
of recurrent restenosis and stent thrombosis. This case
also demonstrates that BVS can be successfully used for
the treatment of diffusely diseased, heavily calciﬁed ves-
sels, as well as in systematic 2-stent strategies for the
treatment of bifurcation lesions. Follow-up angiographysuggests that as long as meticulous lesion preparation,
appropriate BVS sizing, and adequate post-dilation are
performed, BVS can achieve excellent results, at least at
early follow-up. Longer-term data are, however, required
to fully investigate the role of BVS in these complex
lesions.
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